What Is the Maximum Daily Dose of Ezetimibe–Simvastatin, and What Risks Does Overdosing Pose?

For adults with hypercholesterolemia or mixed dyslipidemia, the maximum recommended daily dose of the combination tablet containing sitosterol and ezetimibe—commonly marketed as “Sesame Hibomib” in certain regions—is 10 mg of ezetimibe. This fixed-dose formulation typically contains 10 mg ezetimibe and 2 g of plant sterols (including sitosterol), and no higher dosage is approved or supported by clinical evidence.

Exceeding the recommended dose does not confer additional lipid-lowering benefit and may increase the risk of adverse effects. While ezetimibe is generally well tolerated, doses above 10 mg/day have not been studied extensively in humans and are not authorized for clinical use. Potential risks associated with supratherapeutic dosing include elevated liver transaminases, gastrointestinal disturbances such as diarrhea or abdominal discomfort, and—rarely—hypersensitivity reactions. Concomitant use with statins may further amplify hepatobiliary monitoring requirements.

Clinical guidelines, including those from the American College of Cardiology and the European Atherosclerosis Society, emphasize that ezetimibe’s efficacy plateaus at 10 mg once daily, and dose escalation is neither indicated nor beneficial. Patients requiring more intensive LDL-cholesterol reduction should be evaluated for alternative or adjunctive therapies—including higher-intensity statins, PCSK9 inhibitors, or bempedoic acid—rather than increasing ezetimibe beyond its established therapeutic window.